BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26609687)

  • 1. Abnormal adrenergic activation is the major determinant of reduced functional capacity in heart failure with preserved ejection fraction.
    Messias LR; Messias AC; de Miranda SM; Wiefels CC; Ferreira AG; Santos LM; Teixeira JA; Marostica E; Mesquita CT
    Int J Cardiol; 2016 Jan; 203():900-2. PubMed ID: 26609687
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of loop diuretic use with exercise intolerance in heart failure with preserved ejection fraction.
    Montero D; Haider T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):138-141. PubMed ID: 29319788
    [No Abstract]   [Full Text] [Related]  

  • 3. Nitrites/Nitrates in Heart Failure With Preserved Ejection Fraction.
    Weber T; Eber B; Wassertheurer S; Hametner B; O'Rourke MF
    J Am Coll Cardiol; 2016 Mar; 67(11):1382-3. PubMed ID: 26988965
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply: Nitrites/Nitrates in Heart Failure With Preserved Ejection Fraction.
    Borlaug BA; Koepp KE; Melenovsky V
    J Am Coll Cardiol; 2016 Mar; 67(11):1383-4. PubMed ID: 26988966
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction.
    Borlaug BA; Koepp KE; Melenovsky V
    J Am Coll Cardiol; 2015 Oct; 66(15):1672-82. PubMed ID: 26449137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ancient Gunpowder and Novel Insights Team Up Against Heart Failure With Preserved Ejection Fraction.
    Paulus WJ; van Heerebeek L
    J Am Coll Cardiol; 2015 Oct; 66(15):1683-6. PubMed ID: 26449138
    [No Abstract]   [Full Text] [Related]  

  • 7. Surrogate end points in heart failure trials.
    Gheorghiade M; Adams KF; Gattis WA; Teerlink JR; Orlandi C; O'Connor CM
    Am Heart J; 2003 Feb; 145(2 Suppl):S67-70. PubMed ID: 12594457
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.
    Zile MR; Bourge RC; Redfield MM; Zhou D; Baicu CF; Little WC
    JACC Heart Fail; 2014 Apr; 2(2):123-30. PubMed ID: 24720918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy.
    Ramahi TM; Longo MD; Cadariu AR; Rohlfs K; Slade M; Carolan S; Vallejo E; Wackers FJ
    Eur Heart J; 2001 May; 22(10):849-56. PubMed ID: 11350094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
    Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
    Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
    Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
    Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
    J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
    Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
    J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular long-axis performance during exercise is an important prognosticator in patients with heart failure and preserved ejection fraction.
    Wang J; Fang F; Wai-Kwok Yip G; Sanderson JE; Feng W; Xie JM; Luo XX; Lee AP; Lam YY
    Int J Cardiol; 2015 Jan; 178():131-5. PubMed ID: 25464236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How to evaluate and treat heart failure with preserved left ventricular ejection fraction].
    Cohen Solal A; Tournoux F; Beauvais F; Tartiere JM
    Therapie; 2009; 64(2):101-9. PubMed ID: 19664403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy.
    Nodari S; Triggiani M; Campia U; Manerba A; Milesi G; Cesana BM; Gheorghiade M; Dei Cas L
    J Am Coll Cardiol; 2011 Feb; 57(7):870-9. PubMed ID: 21215550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A failed improvement in pulmonary function and exercise capacity with carvedilol in congestive heart failure despite an excellent effect on left ventricular function].
    Guazzi M; Pontone G; Trevisi N; Lomanto M; Matturri M; Agostoni P
    Cardiologia; 1998 Feb; 43(2):181-7. PubMed ID: 9557374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA; Lewis GD; McNulty SE; Semigran MJ; LeWinter M; Chen H; Lin G; Deswal A; Margulies KB; Redfield MM
    Circ Heart Fail; 2015 May; 8(3):533-41. PubMed ID: 25782985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.